References
- Bardsley-Elliot A, Noble S. Eletriptan. CNS Drugs 1999; 12:325–33
- VanDenBrink AM, et al. Human middle meningeal and coronary artery contraction to eletriptan and sumatriptan. Cephalalgia 1999;19:398
- Muir DF, et al. Hemodynamic and coronary effects of intravenous eletriptan, a 5HT(1B/1D)-receptor agonist. Clin Pharmacol Ther 1999;66:85–90
- Gupta P, et al. Preclinical in vivo pharmacology of eletriptan (UK-116.044): a potent and selective partial agonist at the 5HT1D-like receptor [abstract]. Cephalalgia 1996;16: 386
- Gupta P, Napier CM, Purdy J. In vitro profile of eletriptan, a new 5-HT-like receptor partial agonist [abstract]. Headache 1997;37: 311–12
- Bouchelet I, et al. Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol Pharmacol 1996. 50:219–23
- Rance DJ. The absorption potential of eletriptan (UK-116, 044) and sumatriptan [abstract]. Cephalalgia 1996. 16:387
- Milton KA, Allen MJ, Abel S. The safety, tolerability and pharmacokinetics or oral and intravenous eletriptan, a potent and selective ‘5-HT1D-like’ receptor partial agonist [abstract]. Headache 1997;37: 324
- Lacey LF, Hussey EK, Fowler PA. Single-dose pharmacokinetics of sumatriptan in healthy volunteers. Eur J Clin Pharmacol 1995;47:543–8
- Johnson BF, Shah A, Law G. The absorption kinetics of eletriptan in migraineurs [abstract]. Cephalalgia 1997;17: 415
- Polli J, et al. Eletriptan, but not sumatriptan, is a substrate for P-glycoprotein. Cephalalgia 2000;20:417
- Milton KA, Tan E, Boyce M. The safety, tolerability, pharmacokinetics and pharmacodynamics of oral eletriptan in young and elderly, male and female subjects [abstract]. Cephalalgia 1998;18:405
- Milton KA, Tan E, Love R. The pharmacokinetic and pharmacodynamic interactions of oral eletriptan and propanolol in healthy volunteers [abstract]. Cephalalgia 1998;18:405
- Jackson NC. Clinical measures of efficacy, safety and tolerability for the acute treatment of migraine: a comparison of eletriptan (20–80 mg), sumatriptan (100 mg) and placebo. Neurology 1998;50 (4 Suppl 4): A377, Apr
- Wells N. Migraine treatment: regaining lost time; new eletripan study results [abstract]. 4th European Headache Federation Congress. 1998
- Goadsby PJ, et al. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Neurology 2000;54:156–63
- Pryse-Phillips W. Comparison of oral eletriptan (40–80 mg) and oral sumatriptan (50–100 mg) for the treatment of acute migraine: a randomised, placebo-controlled trial in sumatriptan-naive patients. Cephalalgia 1999;19: 355–6
- Wells N. Comparison of the effectiveness of oral eletriptan (40–80 mg) and oral sumatriptan (50–100 mg) in reducing the time loss and overall impact of migraine attacks. Cephalalgia 1999;19:354
- Pitman V. Efficacy, safety and tolerability of oral eletriptan (40 mg) for the treatment of acute migraine in adolescents (12–17 years) [abstract]. Headache 2000;40:424–5